We consider inference for data from a clinical trial of treatments for metastatic prostate cancer. Patients joined the trial with diverse prior treatment histories. The resulting heterogenuous patient population gives rise to challenging statistical inference problems when trying to predict time to progression on different treatment arms.
Introduction
We discuss inference for data from a phase III clinical trial for treatments of metastatic prostate cancer. The challenging features are patient heterogeneity due to prior treatment history and the need to include a regression on prostate specific antigen (PSA) as an important longitudinal marker. We conduct semi-parametric Bayesian inference to address these challenges.
To achieve the desired data analysis we develop joint inference for event time data and longitudinal observations of a covariate, with the possibility that some patients are cured.
Let T be the event time and Y be the longitudinal covariate. Most existing approaches are based on factoring the joint model as P (T, Y ) = P (Y )P (T | Y ). The first factor is the longitudinal submodel P (Y ), typically assumed to be a mixed model. The second factor is the survival submodel P (T | Y ). In the following discussion, we use event time, survival time, time to progression and failure time exchangably.
There is an extensive literature on the joint modeling of longtitudinal and event time data without cured fraction (De Gruttola and Tu, 1994; Tsiatis et al., 1995; Lavalley and De Gruttola, 1996; Wulfsohn and Tsiatis, 1997; Dafni and Tsiatis, 1998; Henderson et al., 2000; Xu and Zeger, 2001; Lin et al., 2002; Ibrahim et al., 2004) . A review can be found in Tsiatis and Davidian (2004) . Less work has been published on the joint modeling of longitudinal and event time data with cure. Law et al. (2002) proposed a model with the longitudinal process described by an exponential-decay-exponential-growth model and a mixture model to accomodate cure. The imputed values of the longitudinal measurements are covariates in a proportional hazard model. Brown and Ibrahim (2003) and Chen et al. (2004) implemented inference with alternative cure models. The former assumed that the trajectory of longitudinal process affects the hazard function of MCT cells' progression times.
The latter assumed that the longitudinal process affects the mean of the Poisson distribution. Yu et al. (2004) provide a recent review of joint longitudinal-survival-cure models. 1 Specific to modeling PSA, Carter et al. (1992) demonstrated that the use of PSA readings over time leads to more accurate diagnoses. Lin et al. (2002) considered a latent class model to uncover subpopulation structure for both PSA trajectories and a survival outcome. An important feature is that given latent class membership, the longitudinal marker and outcome are assumed independent. A semi-parametric frailty model is assumed, which includes classspecific baseline hazard functions and accommodates possibly time-dependent covariates.
In the joint analysis of longitudinal and event time data, most researchers assume parametric or semi-parametric models for P (T | Y ). It is difficult to implement non-parametric models for P (T | Y ) because most non-parametric models do not allow straightforward incorporation of a regression on covariates. We propose to use the alternative factorization, P (T, Y ) = P (T )P (Y | T ). We proceed under the Bayesian paradigm. Choosing a non-parametric model for P (T ) is the traditional problem of non-parametric inference for an event time. As a scaler, event time T can be included as a covariate into a parametric P (Y | T ) with great ease and flexibility. Furthermore, it is straightforward to apply nonparametric Bayesian models for P (T ), such as a Dirichlet process prior or a Pólya tree (PT) prior. For P (Y | T ), we propose a mixed effects model as a default choice. Both factorizations leads to the joint model, P (T, Y ), describing the mutual dependence between T and Y .
It is this joint model that ultimately allows improved prediction of the event given repeated measurements of the marker. Pawitan and Self (1993) jointly models event time process and longitudinal marker under the framework of P (T, Y ) = P (T )P (Y | T ). Weibull models are assumed for the infection time and disease occurrence time of AIDS. A generalized linear model is specified for the longitudinal measurements of T4 counts and T4/T8 ratio, with the intercept and slope being functions of the event times. Maximum likelihood estimates are obtained for the parameters.
We use a PT prior to model the failure time process, which can be constructed to give probability one to the set of continuous or absolutely continuous probability measures (Lavine, 1992; Mauldin et al., 1992) . Muliere and Walker (1997) implemented PT models in a survival analysis. Walker and Mallick (1997; 1999) demonstrated the application of PT in hierarchical generalized linear models, frailty models, and accelerated failure time models. Hanson and Johnson (2002) 
A Clinical Study
Androgen ablation (AA) is the preferred treatment for metastatic prostate cancer. AA therapy alters the natural history of the disease by disrupting the growth promoting effects mediated by androgen receptor signaling, which is usually accomplished by medical suppression of testicular endocrine function. Unfortunately, most patients with clinically detectable metastatic disease when the AA therapy started will eventually progress to androgen independent prostate cancer (AIPC). AIPC is a relentlessly progressive disease state, and is the cause of death for the vast majority of men in whom it develops. By this mechanism, prostate cancer leads to an annual death toll of more than 27,000 men in the United States.
To date, no treatment has been found to be curative for AIPC, and it is only fairly recently that some therapies are shown to alter the natural history of the disease. A chemotherapy demonstrated a survival advantage over historical results in a phase II trial conducted at M.D. Anderson Cancer Center (Ellerhorst et al., 1997) . This therapy, dubbed KA/VE, treats 3 patients with ketoconazole and doxorubicin alternating with vinblastine and estramustine.
Then a phase III trial of conventional AA therapy versus AA therapy plus three 8-week cycles of KA/VE was conducted at M.D. Anderson Cancer Center. The aim of this trial was to investigate whether better clinical benefit can be achieved by applying the chemotherapy "early", i.e., before the metastatic prostate cancer develops into the far-advanced AIPC.
The two treatment arms are denoted by AA and CH, respectively. The patient population includes metastatic prostate cancer patients whose high risk of developing AIPC justifies long-term, sustained, androgen ablation. The primary endpoint is the time to progression (TTP) to AIPC, which is diagnosed by the following criteria: 1) Symptoms attributed by the treating physician to reflect progressive cancer; 2) Radiographic progression; 3) Rising PSA, with value greater than 1 and doubling time < 9 months; 4) Treatment with chemotherapy.
The first 3 also require demonstration of testosterone < 50 and withdrawal of antiandrogens.
More details about the clinical trial can be found in Milikan et al. (2007) .
Besides the TTP, we also observed the longitudinal measurements of prostate specific antigen (PSA) level from each patient. Carter et al. (2006) demonstrated that PSA velocity is associated with prostate cancer death even 10-15 years before diagnosis. To further improve the understanding of this important marker we propose to build a joint model of the TTP and the PSA measurements.
To statisticians, a challenge posed by this clinical trial is that considerable heterogeneity exists among the patients. Before coming to M.D. Anderson Cancer Center to seek treatment for the metastatic prostate cancer, these patients had been treated by different physicians with different therapies at different institutions. These differences might have a long-term impact on the development of prostate cancer. Second, there is no completely satisfactory way to define "early" in the natural history of metastatic prostate cancer. As a practical solution, the clock start of the trial is defined as the initiation of the AA therapy. Thus at the beginning of the trial, the true stage of cancer might not be exactly the same for each patient.
4
We use v = 1, 2 to denote the two treatment arms (1 for CH and 2 for AA). Let n v be the number of subjects in each arm. For the i-th subject on arm v, we use y vi = {y vij , j = 1, · · · , m vi } to denote the longitudinal measurements, where m vi is the total number of repeated measurements for patient i under treatment v. We define T vi to be the TTP, which is the time between the start of the CH/AA treatment and the progression to AIPC. We use t vi to denote the censoring time for censored observations, and the actual TTP for noncensored observations. We introduce a failure indicator d vi with d vi = 1 if T vi = t vi and
The number of observed and unobserved TTP in each arm are denoted by n v1 and n v0 respectively. In summary, the observed data from each subject is (y vi , t vi , d vi ).
We use [X] and [X | Y ] to generically indicate the probability model for a random variable X and the conditional distribution of X given Y .
The Likelihood
We define the sampling model for the observed data (y vi , t vi , d vi ) from each patient. If d vi = 1, the progression time T vi is observed. Therefore all subjects with d vi = 1 belong to the susceptible group. On the other hand, we only observe T vi > t vi when d vi = 0. In this case the subject could be either in the susceptible group or in the cure group. We define a variable ω vi = 0/1 indicating membership in the cure/susceptible group. For d vi = 1, we have ω vi ≡ 0 by definition, and T vi = t vi . The following discussion simplifies greatly by introducing latent variables T vi and ω vi for subjects with censored TTP, d vi = 0.
If ω vi = 0, the subject is at risk of developing the endpoint event. We assume T vi to be a random sample from a distribution G v , i.e., [T vi 
is the density function of G v . If ω vi = 1, the subject is a long-term survivor. We assume T vi = t c , where t c is an extremely long TTP that could not be observed in the clinical trial. Thus Given T vi , the longitudinal measurements y vi are assumed to arise from a mixed effects In summary, the likelihood factors corresponding to (
Note that L vi0 is an augmented likelihood with latent variable T vi and ω vi .
For L vi0 , the two values taken by ω vi lead to two models of different dimensions. If
we have a model with T vi being a random parameter. In contrast, T vi is fixed at T vi = t c if ω vi = 1. Such a change in dimension complicates posterior simulation (Green, 1995) . We use the pseudo prior approach by Carlin and Chib (1995) to avoid this complication. In words,
we augment the smaller probability model under ω vi = 1 by defining a prior probability model for a hypothetical T vi (but keep t c in the regression for y vi ). The new variable T vi has no meaningful interpretation under ω vi = 1. It is only introduced to match the model dimensions. See Zhang et al. (2008) for details of the pseudo prior choice.
The Prior Probability Model
We assume prior independence, [Ψ, For the unknown survival distribution G v , we consider two choices. The first choice is a parametric model, which assumes G v to be indexed by a finite-dimensional parameter vector. In this case the prior specification only involves assigning prior distributions to these parameters. Recall that G v is the therapy-specific marginal distribution of TTP for the susceptible groups, which contains patients that are different in many important aspects.
A parametric model may not suffice to characterize the complexity of G v . This difficulty motivates the second choice, adopting a non-parametric method. A Bayesian non-parametric prior defines G v as a random probability measure, i.e., we assume a distribution for the
Specifically, we assume G v to have a PT prior, denoted by 
Posterior Inference and Model Validation
To facilitate discussion, we define the following notation. The set of observed and unobserved TTPs under treatment v are denoted by t
to be the set of unknown indicators of cure. Without loss of generality, we assume that d vi = 0 for i = 1, · · · , n v0 , and d vi = 1 for
and p v . We have the full posterior distribution: We compare the proposed model with four natural alternatives. Details of the competing models and results are described later, in Section 5. We use the conditional predictive ordinates (CPO) proposed by Gelfand et al. (1992) to compare different models.
The CPO for subject i in group v (henceforth subject (v, i)) is defined as the posterior predictive distribution evaluated for the observation from subject (v, i), conditional on all the data minus the response from subject (v, i).
Then we compute a summary statistic called the logarithm of the pseudomarginal likelihood (LPML),
. A small value of LP M L suggests disagreement between the observations and the model. Gelfand et al. (1992) show how the CPO for each subject, in our case v = 1, 2 and i = 1, . . . , n v , can be evaluated through an importance sampling scheme. We describe the computation of CPO in Zhang et al. (2008) . We validate the survival and cure aspect of the model based on subject specific martingale residuals (Barlow and Prentice, 1988; Therneau et al., 1990; Lin et al., 2002) .
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We return to the clinical trial from Section 2. The phase III trial for advanced prostate cancer had a total enrollment of 286 patients, with n 1 = 137 in the CH arm and n 2 = 149 in the AA arm. Starting from the diagnosis of prostate cancer, the PSA level of each patient was monitored for up to 10 years. On average, about 30 PSA measurements were collected from each patient. We use y vij (j = 1, · · · , m vi ) to denote the log-transformed longitudinal PSA measurement, y vij = log(1 + P SA). The age at which y vij was recorded is denoted by s vij . As reference points, the age at diagnosis of prostate cancer is denoted by u vi0 , and the age at the initiation of the CH/AA treatment is denoted by u vi1 . The number of observed TTP events in the two treatment arms are n 11 = 87 and n 21 = 98, respectively. Figure 1 shows the Kaplan-Meier estimates of the survival function under the two treatments. There are plateaus at the end of the curves. This observation suggests that a significant portion of subjects might have an excessively long event time and a cure model is appropriate.
PSA level normally increases as the prostate enlarges with age. When prostate cancer develops, however, it increases much faster. The typical effect of a treatment on PSA level is a sharp drop in PSA level immediately after the treatment. Then gradually, the body adjusts to offset the treatment effect, and the PSA level bounces back. The speed of rebound depends on the progress of cancer. Figure 2 plots the longitudinal profiles of four randomly selected patients. Note the variability among the profiles. Exploratory analysis indicates a negative correlation between the PSA slope and TTP. Based on these considerations, the longitudinal
where (x) + = x if x > 0, and (x) + = 0 otherwise. We assume independent normal residuals, e vij iid ∼ N (0, σ 2 ). The first two terms define a line with intercept θ 0vi and slope θ 1vi , describing the baseline linear trend of PSA over age. The coefficients are subject-specific. Parameters η v and φ 1v model the size and the slope of the drop after the intervention with CH or AA. and φ 0vi model the size and the slope of the drop due to the initial therapy right after the diagnosis of prostate cancer. Since we have no information about the initial therapy, we assume γ 2vi and φ 0vi to vary individually. We use γ 1v to model the average change of slope in the baseline trend, induced by treatment v. Finally, model (3) reflects our belief that subjects with flatter longitudinal profiles take longer to progress. To see this, first we observe that in (3) the slope after treatment, i.e., the coefficient of (s vij − u vi1 ) + , is
Here ξ v is constrained to be positive. With T vi changing between 0 and +∞, the slope changes from θ 1vi + γ 1v to 0. We substitute a realistic upper bound for the limiting T vi → ∞ using t c = 18 years. Matching with the earlier notation [y vi | T vi , Ψ] used in (2), we have Ψ = (θ 0 , θ 1 , γ 1 , γ 2 , η, φ 0 , φ 1 , ξ, σ 2 ). Here
, and θ 1 ,γ 2 , φ 0 , φ 1 , ξ are defined in the same fashion. In (3) we use u(T vi ) = exp(−ξ v T vi ) − 1. In summary, besides TTP, the covariates considered include age, treatment, and time under treatment. The dotted lines in Figure 2 show the fitted values of the PSA profiles.
As for the PT priors,
That is, the two PTs are centered around the same distribution a priori. The matching hyperprior parameters for the two PT priors ensures that posterior inference about differences between the two treatment groups reflects the evidence from data.
For the centering measureG, we assume a Weibull distribution,G(t) = Weibull(t; τ, β). Here β and τ are, respectively, the shape and scale parameter. The partition Π is specified by the dyadic quantile sets ofG. The elements of A at the mth level are specified to be c · m 2 , with c being a constant.
The mixture probability p v is assumed to be U nif (0, 1), i.e., a p = b p = 1. The prior of Ψ and other hyperprior parameters are specified as follows. We assume ( 
+ and e vij ∼ N (0, σ 2 ). The survival submodel P (T | Y ) is assumed to be a proportional hazard model with a cure fraction p v . The mean longitudinal process, f vi (s vij ), together with the PSA slope, f vi (s vi ) = ∂f vi (s vi )/∂s vi , are included as time-dependent covariates (Yu et al., 2004) . We assume the following hazard function,
where h v0 (t) is the baseline hazard and (ζ 1v , ζ 2v ) are scaling parameters. Under M 4 , we model h v0 (t) by a piecewise constant function. For 0 < q 1 < q 2 < · · · < q J−1 < ∞, we assume The inferior performance of M 5 suggests that the Weibull hazard assumption might be too restrictive for our data.
The marginal distribution of TTP. The estimated cure probabilities p v (v = 1, 2) for the CH and AA treatments are 0.167 and 0.154, respectively. For advanced prostate cancer patients, here "cure" means that those patients take a very long time to progress to AIPC. Figure 3a shows the estimated densities of TTP in the susceptible group, E(G v | Y , t, d), under the two treatments. The horizontal axis is in years after the treatments. For comparison, Figure 3b plots the posterior estimate of Weibull densities under M 2 . Figure 3 clearly shows deviation from the parametric Weibull distribution. For example, there is a small bump in the CH density curve around 7.5, which is also visible in the Kaplan-Meier estimates in Figure 1 .
This feature can not be captured by M 2 . In Figure 1 we also plot the posterior estimate of the survival function under model M 1 , where TTP are assumed to arise from the mixture of a point mass at t c and an unknown distribution G v . Finally, posterior uncertainty on G v is illustrated in Figure 4 by plotting ten random samples from the posterior distributions.
Because Pólya trees with a fixed partition have discontinuities at the partition points, we have conducted kernel smoothing on the PT densities in both Figure 3 and 4.
The dependence of event times on longitudinal profiles. Under model M 1 , different PSA profiles lead to different posterior distributions of T vi . In Figure 5 we compare the PSA profiles in the first column, the estimated posterior probability of "cure" P (ω vi = 1) and the conditional densities of (T vi | ω vi = 0) in the second column, and the estimated hazard curves given ω vi = 0 in the third column, from four patients with censored TTP. Each row corresponds to one patient, with the first two under treatment CH, and the last two under AA. We only plot the PSA profiles after initiation of the therapies. Figure 5 demonstrates the flexible nature of M 1 . Each patient has a hazard curve of a different shape.
The longitudinal model parameters. Furthermore, the drop induced by CH therapy lasts longer.
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Continuously reassessing the risk of progression. Given a currently observed PSA profile, we can use the proposed method to obtain the predictive distribution of TTP. The predictive distribution provides a good assessment of progression risk. With additional PSA measurements being observed, the predictive distribution can be updated to reflect newly obtained information.
We demonstrate this learning process in Figure 7 . The left panel plots the PSA profiles of two hypothetical patients from the AA arm. Each point denotes a PSA measurement.
The two patients have their PSA level measured at the same time points after treatment.
Within the first two years the two PSA profiles are identical, and then they deviate: the first patient's PSA level stays low, while the second patient's PSA level gradually goes up.
The center panel shows the continuously updated posterior estimates of P (ω = 1 | data), 
Discussion
We have proposed an approach for the joint modeling of event times and longitudinal mea- The proposed approach can readily be generalized to problems with more than two treatments. Also, the longitudinal data model (3) is appropriate for the discussed application to the prostate cancer trial. In general, any other model with a regression on the event time could be used.
